Aaron Lisberg News Today

The application is based on results of the phase 3 TROPION-Lung01 trial of datopotamab deruxtecan in nonsquamous non–small cell lung cancer (NSCLC), first presented at the 2023 European Society for Medical Oncology Congress.

Aaron Lisberg, MD, provides a look at an upcoming Rapid Readout program looking at the results of the TROPION-Lung01 study investigating Dato-DXd in previously treated patients with advanced/metastatic NSCLC.

Patients with previously treated, advanced NSCLC had longer progression-free survival with Dato-DXd than with docetaxel in a phase 3 study.

Patients with previously treated, advanced NSCLC had longer progression-free survival with Dato-DXd than with docetaxel in a phase 3 study.

Still some unanswered questions about benefit over other drug regimens, expert says

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Oct 23, 2023--

AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan reduced the risk of disease progression or death by 25% in overall population and by 37% in patients with non-squamous tumors Datopotamab...

The Trop-2 directed antibody drug conjugate datopotamab deruxtecan demonstrated a statistically significant improvement in progression-free survival vs docetaxel in patients with advanced or metastatic non–small cell lung cancer, however those with squamous histology did not experience a benefit.

Datopotamab deruxtecan not only demonstrated a statistically significant improvement over chemotherapy for breast cancer and docetaxel for non–small cell lung cancer (NSCLC), but the intervention therapy had less toxicity.

Positive results from the pivotal TROPION-Lung01 Phase III trial showed that datopotamab deruxtecan demonstrated a statistically significant improvement for the primary endpoint of...